21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

§ 211.65 Equipment construction

(a) Equipment shall be constructed so that surfaces that contact components, in-process materials, or drug products shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.

(b) Any substances required for operation, such as lubricants or coolants, shall not come into contact with components, drug product containers, closures, in-process materials, or drug products so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 211.65

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Drugs).

  • Equipment construction - reactive surfaces 50
  • Substances That Come in Contact 5

Warning letters citing § 211.65

1 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 211.65

Amendment history

Federal Register documents that created or amended this section.